Literature DB >> 19654308

Migratory and antigen presentation functions of IFN-producing killer dendritic cells.

Nourredine Himoudi1, Mengyong Yan, Gerben Bouma, Daniel Morgenstern, Rebecca Wallace, Ben Seddon, Jo Buddle, Ayad Eddaoudi, Steven J Howe, Nichola Cooper, John Anderson.   

Abstract

The CD11c(int) B220(+) NK1.1(+) CD49(+) subset of cells has recently been described as IFN-producing killer dendritic cells (IKDC), which share phenotypic and functional properties with both dendritic cells and natural killer cells. We have previously shown that IKDCs within murine bone marrow-derived DC preparations are essential for the antitumor activity of unpulsed DCs. Here we show that bone marrow-derived IKDCs (BM-IKDC) migrate in vivo into tumors and thence to tumor draining lymph nodes, where they highly express MHC class II and costimulatory molecules. In vitro, freshly isolated BM-IKDCs, fluorescence-activated cell sorted to homogeneity, have no intrinsic antigen presentation function unless cocultured with tumor target cells. On killing of target cells, they can cross-present antigens to stimulate antigen-primed CD8 T cells and can also present antigens to antigen-primed CD4 cells. In vivo, in mice lacking class I-restricted antigen-presenting cell function, robust proliferation of antigen-specific T cells is achieved after adoptive transfer of BM-IKDCs at an injection site distant to the tumor site. Therefore, BM-IKDCs are capable of cytotoxic killing of tumor targets and also of potent antigen presentation after encountering antigen in the context of a viable target cell.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19654308     DOI: 10.1158/0008-5472.CAN-09-0501

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Tolerogen-induced interferon-producing killer dendritic cells (IKDCs) protect against EAE.

Authors:  Eduardo Huarte; Agnieszka Rynda-Apple; Carol Riccardi; Jerod A Skyberg; Sarah Golden; Maryclare F Rollins; Andrew G Ramstead; Larissa O Jackiw; Massimo Maddaloni; David W Pascual
Journal:  J Autoimmun       Date:  2011-10-22       Impact factor: 7.094

Review 2.  Immunological off-target effects of imatinib.

Authors:  Laurence Zitvogel; Sylvie Rusakiewicz; Bertrand Routy; Maha Ayyoub; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2016-03-31       Impact factor: 66.675

3.  A role for pre-mNK cells in tumor progression.

Authors:  Carolyn Rosinsky; Paul Andrew Antony
Journal:  J Immunother Cancer       Date:  2016-03-15       Impact factor: 13.751

4.  Depletion of B220+NK1.1+ cells enhances the rejection of established melanoma by tumor-specific CD4+ T cells.

Authors:  Kyle A Wilson; Stephen R Goding; Harold R Neely; Kristina M Harris; Paul Andrew Antony
Journal:  Oncoimmunology       Date:  2015-04-01       Impact factor: 8.110

Review 5.  Revisiting the Prominent Anti-Tumoral Potential of Pre-mNK Cells.

Authors:  Fanny Guimont-Desrochers; Sylvie Lesage
Journal:  Front Immunol       Date:  2013-12-11       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.